IPO - Profile

Summary

We are a clinical-stage biologics company focused on discovering and developing a novel class of engineered precision biologics (EPBs), using our proprietary expanded genetic code technology platform that allows us to incorporate, in a site-specific manner, synthetic amino acids (SAAs) into proteins within living cells. Our product candidates are designed to overcome the inherent limitations of conventional conjugation approaches that use natural amino acids for non-site-specific conjugation, offering potential safety and efficacy benefits to treat patients across multiple therapeutic areas. We believe that our technology allows us to engineer a More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$18.00 7,000,000 Positive High 21.42%

Offering Team

  • Legal counsel
  • Cooley LLP
  • Auditors
  • Deloitte & Touche LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 17 Jun, 2021

Offer 18 Jun, 2021

Look Ahead

Lock Up Expiry Dec 18, 2021

IPO Terms

Offer Price $18.00
Offer Size 7M

Market Sentiments

Stock Price